This article is more than 5 years old. Information may no longer be current.

FDA requests more information from Avedro in corneal cross-linking NDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Avedro Inc. announced it plans on working closely with the U.S. Food and Drug Administration to answer the organization’s questions on its New Drug Application for the riboflavin ophthalmic solution/KXL System.

In the press release, David Muller, MD, PhD, Avedro CEO, explained, “While we do not yet have an estimate on how long it will take to resolve the issues, we are confident that we can adequately answer their questions.”

If approved, the riboflavin ophthalmic solution/KXL System would treat keratoconus and corneal ectasia, according to the release.